Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Lawmakers split after ...

After Balancer and Yearn suffered major exploits, new entrants like Axis are betting that transparency and off-chain ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...

Plume is bringing real-world yield to Solana with the rollout of its Nest vaults, giving the network’s users direct access to ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...